Cargando…
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
OBJECTIVE: Canagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorp...
Autores principales: | Polidori, David, Sha, Sue, Mudaliar, Sunder, Ciaraldi, Theodore P., Ghosh, Atalanta, Vaccaro, Nicole, Farrell, Kristin, Rothenberg, Paul, Henry, Robert R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714520/ https://www.ncbi.nlm.nih.gov/pubmed/23412078 http://dx.doi.org/10.2337/dc12-2391 |
Ejemplares similares
-
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
por: Polidori, David, et al.
Publicado: (2013) -
Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
por: Sha, Sue, et al.
Publicado: (2014) -
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
por: Powell, David R, et al.
Publicado: (2019) -
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
por: Sha, S., et al.
Publicado: (2015) -
OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
por: Powell, David, et al.
Publicado: (2019)